-
Advancing Liver Cancer Care: Join the EASL Liver Cancer Summit 2025 in Paris
The EASL Liver Cancer Summit 2025 will take place in Paris from February 20-22, bringing together leading experts to discuss the latest developments in liver cancer diagnosis, prognosis, and treatment.…
-
Final Results from the NATALEE Trial: Ribociclib in Early Breast Cancer
New data from the NATALEE trial reinforce the efficacy of ribociclib in combination with endocrine therapy for HR-positive, HER2-negative early breast cancer. With a median follow-up of 33.3 months, the…
-
Latest Insights in HER2+ Early Breast Cancer: KATHERINE Trial Final Analysis
New findings from the KATHERINE trial, published in The New England Journal of Medicine, confirm that trastuzumab emtansine (T-DM1) continues to provide superior survival benefits over trastuzumab alone in HER2-positive…
-
Dr. Nan Bi Discusses Advances in Radiotherapy for NSCLC in 2024 | 2024 Precision Medicine Conference on Lung Cancer
At the recently held 2024 Precision Medicine Conference on Lung Cancer, Dr. Nan Bi from the Cancer Hospital Chinese Academy of Medical Sciences, delivered a presentation titled “Advances in Radiotherapy for NSCLC in 2024.” The talk covered key developments in radiotherapy combined with targeted therapy, radiotherapy combined with immunotherapy, and technological advancements in radiotherapy. In…
-
Professor Jun Ma: Advancing Frontiers, Updating Guidelines, and Accelerating the Globalization of Hematologic Cancer Treatment
From January 17 to 19, 2025, the Chinese Society of Clinical Oncology (CSCO) Leukemia, Lymphoma, and Multiple Myeloma Expert Committee Meeting & 2025 CSCO Hematologic Oncology Conference was held in the scenic city of Haikou. This high-profile event brought together leading experts from China and abroad to discuss the latest advances in leukemia, lymphoma, and…
-
Transarterial Chemoembolization (TACE) Combined with Camrelizumab and Rivoceranib Versus TACE Alone in Unresectable Hepatocellular Carcinoma
CARES-005 was a multicenter, open-label, randomized phase 2 study enrolling 200 patients with unresectable HCC. Patients were assigned to either TACE plus camrelizumab (200 mg IV, Q3W) and rivoceranib (250…
-
Voices from China at ESMO Asia: Dr. Rongbo Lin’s Team Reveals a Novel Treatment for Refractory Cancer Pain with Promising Potential to Improve Patient
________________________________________ Study Overview This study employed a standard 3+3 dose-escalation design, enrolling patients with a Numerical Rating Scale (NRS) pain score of 3–6 who reported unsatisfactory pain control despite 1–2…
-
Unraveling HLA Class I Expression in Breast Cancer: A Step Towards Precision Immunotherapy
At the San Antonio Breast Cancer Symposium 2024, Dr. Paula Ines Gonzalez Ericsson presented important research on HLA class I expression in breast cancer and its implications for immunotherapy response. Her…
Connecting Medical Expertise through Media